Financière de Tubize Past Earnings Performance
Past criteria checks 3/6
Financière de Tubize's earnings have been declining at an average annual rate of -16.6%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 85.9% per year.
Key information
-16.6%
Earnings growth rate
-14.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 85.9% |
| Return on equity | 4.9% |
| Net Margin | n/a |
| Next Earnings Update | 25 Jul 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Financière de Tubize makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 88 | 0 | 0 |
| 30 Sep 23 | 0 | 89 | 0 | 0 |
| 31 Dec 22 | 0 | 85 | 0 | 0 |
| 30 Sep 22 | 0 | 54 | 0 | 0 |
| 30 Jun 22 | 0 | 320 | 1 | 0 |
| 31 Mar 22 | 0 | 350 | 1 | 0 |
| 31 Dec 21 | 0 | 84 | 0 | 0 |
| 30 Sep 21 | 0 | 210 | 1 | 0 |
| 30 Jun 21 | 0 | 336 | 2 | 0 |
| 31 Mar 21 | 0 | 298 | 2 | 0 |
| 31 Dec 20 | 0 | 261 | 2 | 0 |
| 30 Sep 20 | 0 | 263 | 2 | 0 |
| 30 Jun 20 | 0 | 266 | 1 | 0 |
| 31 Mar 20 | 0 | 275 | 1 | 0 |
| 31 Dec 19 | 0 | 284 | 1 | 0 |
| 30 Sep 19 | 0 | 259 | 1 | 0 |
| 30 Jun 19 | 0 | 235 | 1 | 0 |
| 31 Mar 19 | 0 | 260 | 1 | 0 |
| 31 Dec 18 | 0 | 285 | 1 | 0 |
| 30 Sep 18 | 0 | 307 | 1 | 0 |
| 30 Jun 18 | 0 | 329 | 1 | 0 |
| 31 Mar 18 | 0 | 308 | 1 | 0 |
| 31 Dec 17 | 0 | 286 | 1 | 0 |
| 30 Sep 17 | 0 | 257 | 1 | 0 |
| 30 Jun 17 | 0 | 229 | 1 | 0 |
| 31 Mar 17 | 0 | 205 | 1 | 0 |
| 31 Dec 16 | 0 | 181 | 0 | 0 |
| 30 Sep 16 | 0 | 205 | 0 | 0 |
| 30 Jun 16 | 0 | 229 | 0 | 0 |
| 31 Mar 16 | 0 | 221 | 0 | 0 |
| 31 Dec 15 | 0 | 213 | 0 | 0 |
| 30 Sep 15 | 0 | 161 | 0 | 0 |
| 30 Jun 15 | 0 | 109 | 1 | 0 |
| 31 Mar 15 | 0 | 85 | 1 | 0 |
| 31 Dec 14 | 0 | 61 | 0 | 0 |
| 30 Sep 14 | 0 | 66 | 0 | 0 |
| 30 Jun 14 | 0 | 71 | 0 | 0 |
| 31 Mar 14 | 0 | 58 | 1 | 0 |
| 31 Dec 13 | 0 | 44 | 1 | 0 |
| 30 Sep 13 | 0 | 48 | 1 | 0 |
| 30 Jun 13 | 0 | 51 | 1 | 0 |
Quality Earnings: TUB has high quality earnings.
Growing Profit Margin: Insufficient data to determine if TUB's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TUB's earnings have declined by 16.6% per year over the past 5 years.
Accelerating Growth: TUB's earnings growth over the past year (3.5%) exceeds its 5-year average (-16.6% per year).
Earnings vs Industry: TUB earnings growth over the past year (3.5%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: TUB's Return on Equity (4.9%) is considered low.